Resverlogix Corp.
🇨🇦XTSE.RVXCanadaHealthcare
PriceCA$0.11+0.02 (+22.22%)
Latest anomalies
Negative 2 detected in the last 120 days
- High: 2
- Medium: 3
- Low: 0
12-1M momentum: flipped sign, from positive to negative
52-week low: the price is trading close to this level
Debt to equity: a sudden spike above its trailing quarter average
Long-term debt to equity: a sudden spike above its trailing quarter average
Current ratio: below the level we flag as a liquidity warning
Free with a Finzer account.
Profile
- Healthcare
- Biotechnology
- Canada
Identity
- Exchange
- Toronto Stock Exchange . XTSE
- Type
- Stock
- ISIN
- CA76128M1086
- CUSIP
- 76128M108
Company
- Employees
- 0
- Headquarters
- Calgary, Canada
- Website
- https://www.resverlogix.com
Market
- Shares outstanding
- 344.3M
- Market cap
- CA$31.51M
Highlights
- Market cap
- CA$31.51M
- EPS LTM
- -CA$0.04calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- -2.84calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- 0%
Fundamentals (LTM)
- Revenue
- CA$00%unchanged year on year
- Net income
- -CA$11.08M-3.16%down year on year
- Gross margin
- Not reported
- Free cash flow
- -CA$3.96M+34.81%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Resverlogix Corp. is a company in the healthcare sector, listed on Toronto Stock Exchange (Canada) under the ticker RVX. Its market capitalisation is CA$31.51M, from 344.3M shares outstanding, as of . Across the 250 trading sessions to the shares traded between CA$0.09 and CA$0.15, and the last close of CA$0.11 sits 33% of the way up that range. The company is headquartered in Calgary, Canada.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.